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Abstract
Background: Antipsychotic therapy can reduce severe symptoms of psychiatric disorders, however, data on school
performance among children on such treatment are lacking. The objective was to explore school performance
among children using antipsychotic drugs at the end of primary education.
Methods: A cross-sectional study was conducted using the University Groningen pharmacy database linked to
academic achievement scores at the end of primary school (Dutch Cito-test) obtained from Statistics Netherlands.
Mean Cito-test scores and standard deviations were obtained for children on antipsychotic therapy and reference
children, and statistically compared using analyses of covariance. In addition, differences in subgroups as boys
versus girls, ethnicity, household income, and late starters (start date within 12 months of the Cito-test) versus early
starters (start date > 12 months before the Cito-test) were tested.
Results: In all, data from 7994 children could be linked to Cito-test scores. At the time of the Cito-test, 45
(0.6 %) were on treatment with antipsychotics. Children using antipsychotics scored on average 3.6 points
lower than the reference peer group (534.5 ± 9.5). Scores were different across gender and levels of
household income (p < 0.05). Scores of early starters were significantly higher than starters within 12 months
(533.7 ± 1.7 vs. 524.1 ± 2.6).
Conclusion: This first exploration showed that children on antipsychotic treatment have lower school
performance compared to the reference peer group at the end of primary school. This was most noticeable for
girls, but early starters were less affected than later starters. Due to the observational cross-sectional nature of this
study, no causality can be inferred, but the results indicate that school performance should be closely monitored
and causes of underperformance despite treatment warrants more research.
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Background
Childhood psychiatric disorders are of concern because
of the associated negative impact on general wellbeing
across the lifespan, for example, lower educational
achievements [1–5]. The findings in several studies sug-
gest that the adverse impact of childhood onset psychi-
atric disorders on educational attainment is largely
accounted by problems of inattention and conduct. Most
psychiatric disorders present symptom patterns that
cause severe impairment on the emotional, cognitive
and social level, resulting into the child being unable to
carry out his/her educational potential. Esch et al. [4]
and Kumpulainen et al. [2] studied the relationship
between psychiatric symptoms and performance level at
school among 8-year-old children. Children facing psy-
chiatric difficulties were more likely to receive extra
tutoring or special education. The probability of getting
special education was highest for attention deficit disor-
ders, anxiety, and oppositional/conduct disorders. Chil-
dren from low socio-economic status families had more
psychiatric symptoms and performed less successfully at
school than children from more advantaged environ-
ments. This suggests that children with psychiatric
symptoms or disorders are more likely to have lower
performance levels at primary school.
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A few studies have shown that psychiatric disorders in
children and adolescents can negatively impact academic
performance. Medical drug treatment with antipsy-
chotics has been proven effective in reducing symptoms
of such disorders.[6] However, it remains uncertain
whether such treatment restores academic performance
since a systematic comparison between drug treated
children and their peers is currently lacking. Insights
into academic performance among this vulnerable group
of children is essential to further optimize care, their
school performance and general well-being. We there-
fore compared school performance among children
using antipsychotic drugs at the end of primary educa-
tion with their peers using an observational cross-
sectional design. We also explored differences across
various relevant subgroups according to sex, ethnicity,
parent household, and household income as well as early
versus late start of drug treatment.
Methods
Study setting
This retrospective cohort study was performed by
linking drug prescription data from the University
Groningen pharmacy prescription database ‘InterAction
Database’ (IADB.nl) to data obtained from Statistics
Netherlands. The IADB database is a longitudinal
pharmacy-dispensing database with detailed patient-
based drug prescription data from 1994 till 2012 from
approximately 600,000 patients in the northern
Netherlands. Prescription rates amongst the database
population have been found to be representative of the
Netherlands as a whole, and the database has been
widely used for research [7]. Each prescription record
contains information on the date of dispensing, the
quantity dispensed, the dose regimen, the number of
days the prescription is valid, the prescribing physician
and the Anatomical Therapeutic Chemical code (ATC
code). Each patient has a unique anonymous identifier
and therefore informed consent was not necessary; date
of birth and sex are known. Due to high patient phar-
macy commitment in the Netherlands, the medication
records for each patient are virtually complete [8]. Ac-
cess to the database for this specific study was granted
by the supervisory board of the IADB.
Statistics Netherlands is a Third Trusted Party for data
linkage in The Netherlands. Datasets such as the Cito-
test, an academic achievement score-test, database and
the IADB.nl database are assigned an unique personal-
ized identification code based on identification informa-
tion such as birth date or social security number.
Statistics Netherlands performed the linkage between
datasets and removed all identification information from
the dataset which could be accessed by the researchers,
hence researchers are unable to identify patients after
linkage of the data. We obtained datasets covering ethni-
city, type households, and income of households. Due to
national regulations confidentiality was warranted by
following the guidelines of disclosure of identities of
individual persons, enterprises, institutions or house-
holds by Statistics Netherlands. Access to the Statistics
Netherlands data and linkage with the IADB was given by
the Customised Services Team of Statistics Netherlands.
Our study population consisted of 7,994 children born
in 1996–2001 from the IADB database, whose outcome
Cito-test scores were available in the Statistics
Netherlands database. For the cross-sectional design at
the end of primary education, we obtained drug pre-
scription data from January 1st 2001 through March 31st
2012.
Individual Cito-test scores from the years 2009–2012
and demographic data on every child, including sex, eth-
nicity, parent household, and household income were
obtained from Statistics Netherlands. We used data reg-
istered until 2012, which represented the most recent
years of the IADB prescription data available at the time
of our study. Household income data of the year 2011
was used, which represented the mid-term of the period
in which the Cito-test scores were available. Also, we ob-
tained parent household information of the year the
Cito-test. We categorized ethnicity as Dutch or non-
Dutch, in which the classification was based on the
mother’s country of birth. Parent household was classi-
fied as being a one-parent or a two-parent household.
The standardized disposable household income in per-
centiles from Statistics Netherlands was used to classify
household income and defined as the gross income of all
household members minus paid income transfers, social
contributions and taxes. The disposable household in-
come was adjusted for the individual family members to
facilitate comparison between the various types of
households. The standardized disposable household in-
come was subsequently apportioned to each of the
household members. In this article household income
was defined as the standardized disposable household in-
come. We classified household income in three groups:
low, middle and high; the maximum year income of the
low income is € 17 374 and the maximum year income
of the middle group is € 25 212.
Definitions of children on antipsychotic treatment and
reference group
Children on antipsychotic drug treatment
We assumed children to have been treated if they had a
prescription for any antipsychotic drug in the year the
Cito-test was taken from January 1st to March 31st
(Fig. 1). We refer to this treatment group as anti-
psychotic users. For each treated child, all prescriptions
for antipsychotic drugs (ATC: N05A) were identified
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from the IADB database. The date of first dispensing of
any antipsychotic drug marked the start of treatment.
We also included children with a prescription in December
the year before the Cito-test was taken, who also had a pre-
scription in April the year the Cito-test was taken. These
children had a prescription for at least 100 days and
therefore probably used antipsychotics during the
period of the test. Children were only included in the
study when they were present in the database for at least
1 year before initiation of antipsychotic treatment.
Start of treatment
The initiation of antipsychotic treatment for each child
was defined by the date of the first dispensing of a pre-
scription for any antipsychotic drug within the study
period (2001–2012). We compared school performance
within the antipsychotic users group according to their
different timing of initiating drug treatment before the
Cito-test, i.e. children with early vs. late start of treat-
ment. We used February in the year the Cito-test as ref-
erence date and we defined antipsychotic users as
starting the treatment within 12 months (late start) and
earlier than 12 months (early start) (Fig. 1).
Reference peer group
We selected children from the IADB database born be-
tween 1996 and 2001 with no prescriptions for any anti-
psychotic drug in their medical history. They were
referred to as non-users.
Academic school performance
Academic performance was operationalized into Cito-test
scores available from Statistics Netherlands. The Cito-test,
is a nationwide used independent, standardized, academic
achievement score-test which informs about the most suit-
able type of secondary education (http://www.iaea.info/
documents/paper_1162d212f6.pdf ). The score is an indi-
cator for the learning achievement of a child; indirectly the
score is an indicator of his or her intelligence, motivation,
concentration, and drives to learn (http://www.iaea.
info/documents/paper_1162d212f6.pdf). The test is taken
in around 85 % of the Dutch primary schools in the first
week of February each year. Standardized Cito-test scores
range from 501 to 550, based on a transformation of the
number of correct answers for two-hundred multiple-
choice questions covering language, arithmetic/mathematic,
and study skills, which indicates the most suitable type of
secondary education (≤523: secondary education leading to
vocational education level 3, 524–528: level 2, 529–536:
level 1, 537–544: secondary education leading to higher
professional education, ≥545: secondary education lead-
ing to university) (http://www.iaea.info/documents/paper_
1162d212f6.pdf). The language part of the Cito-test con-
sists of spelling, reading comprehension, verbs, vocabu-
lary, and writing. Arithmetic/mathematic questions cover
measurements, time, money, fractions, percentages, and
ratios. Study skills questions involve the child’s ability to
process information from dictionaries, tables, graphs,
scheme’s, maps etc.
Statistical analysis
We first conducted descriptive explorative analyses to as-
sess the frequencies of covariates within our antipsychotic
and non-users population. Pearson chi-square tests were
used to compare the frequencies of the baseline character-
istics between comparison groups. In subgroup analyses,
we described crude mean Cito-test scores with standard
deviations for the subgroups and tested for between-
group difference with analysis of variance (ANOVA) (two-
sided). Then we performed multivariate analysis to
describe differences school performance related to chil-
dren with or without antipsychotic treatment across the
levels of the subgroups. We applied analysis of covariance
(ANCOVA) models to estimate mean Cito-test scores
across the different groups (users vs. non-users; early vs.
late starters), initially unadjusted and also subsequently
adjusted for sex, ethnicity, parent household and house-
hold income. A p value <0.05 was considered statistically
significant. All analyses were performed using SPSS 20.0.
Results
Out of the 7994 children registered in the IADB.nl who
could be linked to their Cito-test scores, 45 (0.6 %) chil-
dren were treated with an antipsychotic drug at the time
of the Cito-test of whom 36 were boys (antipsychotic
users, see Fig. 2). Among all children in the total IADB
population, the availability of Cito-test scores was lower
for the antipsychotic drug treated population (17.6 %)
than for the reference population (37.1 %). In addition,
Fig. 2 shows that 32 (71 %) children were early starters
defined as starting treatment with antipsychotics earlier
than 12 months ago, and 13 (17.6 %) were late starters.
Fig. 1 Study design of the different comparator groups
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Table 1 shows that 27 (60.0 %) of the antipsychotic
users had prescriptions for risperidone, followed by 8
(17.8 %) for pipamperone, 7 (15.6 %) for aripiprazole, 2
(4.4 %) for both risperidone and pipamperone, and 1
(2.2 %) for quetiapine. Baseline characteristics among
our study population varied only for the subgroup sex.
Boys comprised 47.3 % of non-users and 80.0 % of anti-
psychotic users. Overall, boys were more frequently
treated with antipsychotic drugs than girls. No difference
in the distribution of the frequencies within levels of the
subgroups between antipsychotic users and reference
group was found for the subgroups ethnicity, parent
household and household income.
In univariate analyses children using antipsychotics at
the time of the Cito-test scored on average 3.6 points
lower (p < .05) on their Cito-test compared with the
non-using general population (Table 2). No significant
difference was detected between the mean Cito-test
scores of boys in the users group and boys in the non-
users group. However, girls in users group had signifi-
cantly lower average Cito-test scores (525.2 ± 7.5) than
girls in reference group (534.1 ± 9.5). The subgroup of
Dutch children using antipsychotic drugs during the
Cito-test (531.6 ± 10.4) performed worse than Dutch
children who did not use antipsychotic drugs (534.9 ±
9.4). The difference in mean Cito-test scores between
non-Dutch users and non-Dutch non-users was not sta-
tistically significant. Also, both groups did not differ with
respect to parent household and low household income.
There was a significant difference between mean Cito-
test scores of users and non-users in middle (non-users:
534.3 ± 9.2 vs. antipsychotic users: 529.7 ± 10.8) and high
household income (non-users: 538.1 ± 8.4 vs. anti-
psychotic users: 530.9 ± 9.2). Antipsychotic users who
started their treatment late (≤12 months) had a lower
average score (524.9 ± 9.1) than those who started early
(533.4 ± 10.1).
In multivariate analysis, Cito-test scores of non-users
and users were independently and statistically different
across levels of household income (p value .037). Al-
though, children from one-parent households performed
lower than two-parent households, this finding was not
statistically significant. The same applied for children
with non-Dutch ethnicity vs. Dutch ethnicity.
After adjustments for the measured baseline differ-
ences between the comparison groups, the means of
Cito-test scores remained significantly different between
the antipsychotic users (531.4 ± 1.4) and reference group
(534.5 ± .1), p value .024 (Table 3). The adjusted mean
estimates remained similar to the crude mean Cito-test
scores and indicated little differences across the levels of
the subgroups. However, the difference between late
starters and early starters was statistically significant.
Compared with early starters (533.7 ± 1.7) we found a
significantly lower mean Cito-test score for the late
starters (524.1 ± 2.6).
Discussion
The main finding of this explorative study is that chil-
dren using antipsychotics at the time of the Cito-test
show lower academic achievement at the end of primary
school than their peer group. Importantly, girls seem to
be more affected than boys, but those who started earlier
showed similar performance as their peers. To our
knowledge, these data are the first to describe the pri-
mary school performance among children on anti-
psychotic therapy.
Our results are largely in agreement with earlier find-
ings reported by Kumpulainen et al. [2] who demon-
strated in a questionnaire study that children having
psychiatric symptoms are more likely to be low achievers
in school, though it was unknown whether the study
subjects were on drug treatment.
A strength of this study is that we used a nationwide
used, validated and standardized test to determine the
school performance of children and did not rely on self-
reported questionnaires. Information bias is highly un-
likely. Each study year, the Cito-test was taken at the
Fig. 2 Flowchart of the study population. Abbreviation:
AP, anti-psychotic
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same time by the similar amount of children with a simi-
lar average score and the test results are comparable
over the years (http://www.cito.nl/onderzoek%20en%20-
wetenschap/achtergrondinformatie/primair_speciaal_ond
erwijs/eindtoets_onderzoek_achtergrond). It is an object-
ive, quantitative, standardized achievement test, which
represents the learning achievement of a child. Because
we used records from Statistics Netherlands our data is
not influenced by recall bias or subjective measures
often associated with data reported by parents or chil-
dren. Furthermore, we used pharmacy-dispensing re-
cords which is a valid method to obtain information on
actual prescription drug use. Also, it was possible to fol-
low children from the moment of first dispensing to the
year in which the Cito-test was taken. The availability of
prescription history information for at least 1 year before
the Cito-test allowed the possibility for differential
exposure, i.e. early starters versus late starters and con-
current treatment.
An important feature of the cross-sectional nature of
this study design is that we cannot draw causal
conclusions from these data. Several studies reported a
negative association between psychiatric disorders and
educational attainment and school dropout, and the
present findings may indicate that there is already a not-
able difference present at the end of primary school [1,
3–5]. Children using antipsychotics may face learning
difficulties because of their underlying psychiatric dis-
order which may prevent them from carrying out their
educational potential. We did not have information on the
severity of symptoms, underlying diagnoses, or indica-
tions, for which the drugs were prescribed. Importantly,
our study lacks information about possible concurrent
psychosocial interventions or educational school services
received by children in the study population. While it is
possible that their underlying illness is related to a lower
academic performance, it remains uncertain whether anti-
psychotic treatment can be a mediating or causing factor.
A further limitation of our study was the number of
children receiving antipsychotic treatment being rela-
tively small due to low prevalence of psychiatric disor-
ders and relatively low number of children that could be
Table 1 Comparison of the baseline characteristics between non-users and antipsychotic users
Non-users, n (%) Antipsychotic users, n (%) p value (Chi2)





Risperidone + Pipamperone 2 (4.4)
Quetiapine 1 (2.2)
Start of treatment:
Late <12 months 13 (28.9)
Early > 12 months 32 (71.1)
Subgroups:
Sex <.05*
Boys 3748 (47.3) 36 (80.0)
Girls 4179 (52.7) 9 (20.0)
Ethnicity .695
Dutch 7018 (88.5) 39 (86.7)
Non-Dutch 909 (11.5) 6 (13.3)
Parent household .141
Two-parent household 6486 (81.8) 33 (73.3)
One-parent household 1441 (18.2) 12 (26.7)
Household income .134
Low 2674 (33.7) 20 (44.4)
Middle 3038 (38.3) 18 (40.0)
High 2215 (27.9) 7 (15.6)
Abbreviation: n, sample size
* Significant at .05 level
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linked to the Cito-test scores. Therefore, smaller differ-
ences in scores could in some subgroups not be ad-
equately tested.
The prevalence rate of antipsychotic use found in our
study (6 per 1000) is in accordance with the reported
prevalence of 6,8 per 1000 in 2005 by Kalverdijk et al. [9].
In comparable studies from European countries re-
searchers reported overall prevalence rates of 3.2 per 1000
in Germany in 2012, 3.4 per 1000 in France in 2004 and
10,6 per 1000 in Iceland in 2007 [10–12]. Hence, we
might conclude that our population is representative
for the Netherlands as a whole. Importantly, over the
years 2009–2012, children in group eight of all pri-
mary schools who participated in the Cito-test in the
Netherlands had an average overall Cito-test score of
535, which is similar to the average of the reference
group in our study population. In addition, the age
and gender distribution of the general population cor-
responds with the population of the IADB, which in-
dicates that both populations are similar.
Table 2 Results of univariate and multivariate analyses in relation to Cito-test scores including the subgroups
Non-users M ± SD Antipsychotic users M ± SD Subgroups p value Interaction p value
Total 534.5 ± 9.5 530.9 ± 10.5 < .05*
Subgroups:
Sex .075
Boys 535.0 ± 9.4 532.4 ± 10.7 .100
Girls 534.1 ± 9.5 525.2 ± 7.5 < .05*
Ethnicity .785
Dutch 534.9 ± 9.4 531.6 ± 10.4 < .05*
Non-Dutch 531.9 ± 10.0 526.8 ± 11.2 .219
Parent household .301
Two-parent household 535.0 ± 9.4 532.1 ± 10.6 .075
One-parent household 532.4 ± 9.5 527.8 ± 9.9 .099
Household income .037*
Low 531.9 ± 9.7 532.1 ± 11.0 .940
Middle 534.3 ± 9.2 529.7 ± 10.8 < .05*
High 538.1 ± 8.4 530.9 ± 9.2 < .05*
Start of antipsychotic treatment:
Late start (≤12 months) 524.9 ± 9.1 <. 05*a
Early start (>12 months) 533.4 ± 10.1
Abbreviations: n sample size, M mean, SD standard deviation
* Significant at .05 level
a Comparison within the antipsychotic user group
Table 3 Crude and adjusted mean Cito-test scores adjusted for baseline differences of sex, ethnicity, parent household and household
income with ANCOVA analyses
School performance
Crude M ± SD Adjusted M ± s.e. n p value
AP treatment
Antipsychotic users 530.9 ± 10.5 531.4 ± 1.4 45 .024*
Non-users 534.5 ± 9.5 534.5 ± .1 7927
Treatment with:
MPH 531.9 ± 9.5 531.9 ± .6 272 .882
MPH + AP 532.2 ± 10.2 532.2 ± 2.0 22
Start of AP treatment
Late start≤ 12 months 524.9 ± 9.1 524.1 ± 2.6 13 .004*
Early start > 12 months 533.4 ± 10.1 533.7 ± 1.7 32
Abbreviations: AP antipsychotic drug, M mean, SD standard deviation, s.e. standard error, n sample size
*: Significant at the .05 level
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A notable difference was the availability of Cito-test
scores between the drug treated population (17.6 %) and
the reference population (37.1 %). The low number of
Cito-test data can be attributed to the fact that before
2010 the test data reported to Statistics Netherlands was
incomplete due to the availability of the data by a sec-
ondary party. This difference between the antipsychotic
group and the reference group can be explained by the
fact that some children are not obliged to take the Cito-
test in case of severe learning difficulties. For this reason,
the difference in availability of Cito-test scores will prob-
ably give an underestimation of our results.
Antipsychotic treatment was mainly observed in boys
and to a lesser extent in girls which is consistent with
several studies that have reported that antipsychotic
treatment of children predominantly involves male pa-
tients and mainly involves the treatment of disruptive
behavior disorders [9, 12, 13]. Disruptive behavior disor-
ders are more commonly diagnosed in boys than in girls
[14]. Importantly, the differences in school performance
between anti-psychotic users and reference group was
more pronounced among girls than among boys. Girls
seem to be primarily responsible for the significantly
poorer school performance detected for antipsychotics
users. Although no causal conclusions can be drawn
from this study, it seems unlikely that the beneficial ef-
fect of antipsychotic drugs is different for pre-puberal
boys than girls. Our data suggest that the indications for
antipsychotic treatment may be different across sex and
therefore girls may respond differently to their treat-
ment. Consequently, antipsychotic drugs may be less
effective for those specific indications. Such sex differ-
ences in indications for antipsychotics and school per-
formance outcomes need to be further explored in
future studies.
There is a lack of knowledge about the most preferable
initiation and duration of antipsychotic treatment in
childhood. In our data children starting antipsychotic
treatment earlier than 12 months before the testing
period indicated a better average school performance
outcome than late starters. This suggests that children
starting treatment earlier are more likely to have had
more opportunity to adjust and to be treated with the
optimal antipsychotic drug. However, for the interpret-
ation of these results we lack information about the de-
velopment of their psychiatric disorders at different ages
and different symptom patterns that may influence their
school performance.
The results of this study suggest that children with
antipsychotic treatment perform lower on primary
school and this special group of children may be unable
to carry out their educational potential. Antipsychotic
treatment does not appear to entirely restore academic
performance associated with psychiatric disorders. This
highlights the importance of additional (non-pharmaco-
logical) interventions aimed at academic functioning,
notably among girls. This information regarding the
school performance in this specific population could be
useful for parents, teachers, and clinicians. Future re-
search needs to focus on possible reasons for their sus-
ceptibility to underachievement on primary school.
Furthermore, the long-term effects of antipsychotic use
in children should be examined.
Conclusion
In conclusion, this first exploration showed that children
on antipsychotic treatment have lower school perform-
ance compared to the reference peer group at the end of
primary school. This was most noticeable for girls, but
early starters were less affected than later starters. Due
to the observational cross-sectional nature of this study,
no causality can be inferred, but the results indicate that
school performance should be closely monitored and
causes of underperformance despite treatment warrants
more research.
Abbreviations
ADHD: Attention-Deficit/Hyperactivity Disorder; ATC code: Anatomical




This study received no specific funding.
Availability of data and materials
Data will not be shared because of restrictions of the use of data imposed
by the external data source.
Authors’ contributions
Conceived and designed the study: EH PJH TWV JvdS. Acquisition of data: SV
RC HJB. Analyzed the data: SV RC HJB JvdS. Wrote the manuscript: JvdS SV
RC PJH TWV EH. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
By using an unique anonymous identifier number all patient data was
depersonalized. Therefore, use of all patient data was in line with the Dutch
Law for the Protection of Personal Data and the Declaration of Helsinki.
Author details
1Department of Pharmacy, PharmacoTherapy, −Epidemiology & -Economics,
University of Groningen, Antionius Deuginslaan 1, Groningen 9713 AV, The
Netherlands. 2Department of Psychiatry, University of Groningen, University
Medical Center Groningen, Hanzeplein 1, Groningen 9713 GZ, The
Netherlands. 3Department of Pediatrics, Medical Center Leeuwarden, Henri
Dunantweg 2, Leeuwarden 8934 AD, The Netherlands. 4Department of
Epidemiology, University Medical Center Groningen, Hanzeplein 1,
Groningen 9713 GZ, The Netherlands.
Received: 28 June 2016 Accepted: 12 September 2016
van der Schans et al. BMC Psychiatry  (2016) 16:332 Page 7 of 8
References
1. Kessler RC, Foster CL, Saunders WB, Stang PE. Social consequences of
psychiatric disorders; I: educational attainment. Am J Psychiatry. 1995;152(7):
1026–32.
2. Kumpulainen K, Rasanen E, Henttonen I, Puura K, Moilanen I, Piha J,
Tamminen T, Almqvist F. Psychiatric disorders, performance level at school
and special education at early elementary school age. Eur Child Adolesc
Psychiatry. 1999;8 Suppl 4:48–54.
3. Breslau J, Miller E, Joanie Chung WJ, Schweitzer JB. Childhood and
adolescent onset psychiatric disorders, substance use, and failure to
graduate high school on time. J Psychiatr Res. 2011;45(3):295–301.
4. Esch P, Bocquet V, Pull C, Couffignal S, Lehnert T, Graas M, Fond-Harmant L,
Ansseau M. The downward spiral of mental disorders and educational
attainment: a systematic review on early school leaving. BMC Psychiatry.
2014, 14:237-014-0237-4.
5. Veldman K, Bultmann U, Stewart RE, Ormel J, Verhulst FC, Reijneveld SA.
Mental health problems and educational attainment in adolescence: 9-year
follow-up of the TRAILS study. PLoS One. 2014;9(7):e101751.
6. Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive
behaviour disorders in children and youths. Cochrane Database Syst Rev.
2012;9:CD008559.
7. Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LT, Postma
MJ. The population-based prescription database IADB.nl: its development,
usefulness in outcomes research and challenges. Expert Rev Pharmacoecon
Outcomes Res. 2013;13(3):285–92.
8. Strom BL. Pharmacoepidemiology. 4th ed. Chichester: Wiley; 2005.
9. Kalverdijk LJ, Tobi H, van den Berg PB, Buiskool J, Wagenaar L, Minderaa RB,
de Jong-van den Berg LT. Use of antipsychotic drugs among Dutch youths
between 1997 and 2005. Psychiatr Serv. 2008;59(5):554–60.
10. Acquaviva E, Legleye S, Auleley GR, Deligne J, Carel D, Falissard BB.
Psychotropic medication in the French child and adolescent population:
prevalence estimation from health insurance data and national self-report
survey data. BMC Psychiatry. 2009, 9:72-244X-9-72.
11. Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U,
Halldorsson M. Psychotropic drug use among Icelandic children: a
nationwide population-based study. J Child Adolesc Psychopharmacol.
2009;19(6):757–64.
12. Bachmann CJ, Lempp T, Glaeske G, Hoffmann F. Antipsychotic prescription
in children and adolescents: an analysis of data from a German statutory
health insurance company from 2005 to 2012. Dtsch Arztebl Int. 2014;
111(3):25–34.
13. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the
office-based treatment of children, adolescents, and adults with
antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247–56.
14. Frick PJ, Lahey BB, Applegate B, Kerdyck L, Ollendick T, Hynd GW, Garfinkel
B, Greenhill L, Biederman J, Barkley RA. DSM-IV field trials for the disruptive
behavior disorders: symptom utility estimates. J Am Acad Child Adolesc
Psychiatry. 1994;33(4):529–39.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
van der Schans et al. BMC Psychiatry  (2016) 16:332 Page 8 of 8
